GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

Lipocine LPCN · USD

Health Care · US listing · 🇺🇸 United States

Compare

1.72

+9.55%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Lipocine

From its filings with the US Securities and Exchange Commission

SEC filings

Lipocine is based in Salt Lake City, United States and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker LPCN. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $2.0m and a net loss of $9.6m. At that date it held total assets of $17.0m and shareholders' equity of $14.5m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
21 Mar 2014
Employees
14
Head office
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, X1, 84108
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Dr. Spyros PapapetropoulosLead Independent Chairman of the Board$102,223
  • Dr. Mahesh PatelPresident, Chief Executive Officer, Director, since 1997$761,771
  • Dr. Nachiappan ChidambaramSenior Vice President - Research and Development$413,789
  • Ms. Krista FogartyPrincipal Accounting Officer, Corporate Controller$340,588
  • Mr. John HiguchiDirector$64,723
  • Mr. Jeffrey FinkIndependent Director$88,723
  • Dr. Jill JeneIndependent Director$72,223
  • Dr. Richard OnoIndependent Director$84,723

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Lipocine's oral drug delivery technology enables bioavailable drugs with lower dosing requirements.
  • TLANDO XR (LPCN 1111) offers a once daily oral testosterone replacement therapy solution.
  • Lipocine's pipeline includes treatments for NASH cirrhosis and pre-cirrhotic non-alcoholic steatohepatitis.

Weaknesses

  • Lipocine employs only 14 full-time employees, limiting operational capacity.
  • The company's focus on oral drug delivery may restrict broader market applications.
  • Lipocine's lead product TLANDO is an oral testosterone replacement therapy with limited market penetration.

Opportunities

  • Lipocine's LPCN 1144 targets pre-cirrhotic non-alcoholic steatohepatitis with unmet medical needs.
  • The firm's oral therapy for preterm birth prevention addresses a significant healthcare gap.
  • Lipocine's technology could expand into other pharmaceutical applications beyond current focus.

Threats

  • Lipocine's small employee count of 14 may hinder rapid development and market response.
  • The company's reliance on oral drug delivery technology faces potential competition from alternative methods.
  • Lipocine's clinical-stage status means delayed revenue from product approvals.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.